Researchers offer alternative treatment option for hemophilia

The research demonstrates that a protein called P-selectin could be an important factor in blood clotting. Furthermore, by altering its levels in the bloodstream the investigators were able to establish its therapeutic potential.

People with hemophilia have traditionally relied upon intravenous infusion of recombinant Factor VIII clotting protein. However, the new discovery could pave the way for an alternative treatment using P-selectin, a possibility which, according to the researchers, could be much easier and more effective.

Infusion of P-selectin could provide an affordable and effective method of treatment as it is naturally occurring in the body. Patients are also highly unlikely to make antibodies against P-selectin, which has a longer half-life than clotting factors so treatment is likely to be less frequent.

Research investigator, professor Denisa Wagner from Harvard University said: “Our studies in mouse models have shown that inhibition of P-selectin reduces atherosclerosis (hardening of the arteries) and the work of our collaborators shows that the events leading to deep vein thrombosis are reduced. P-selectin inhibitors have also been shown to be anti-thrombotic in early human trials”

Measurement of P-selectin levels in the blood stream may provide a new diagnostic tool to identify people at risk of heart disease and stroke. Levels above baseline could alert clinicians to potentially fatal events. Several pharmaceutical companies are now searching for compounds that target P-selectin.